Search for: "Lambert v. State" Results 161 - 180 of 601
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
22 Dec 2016, 9:10 am by Brian Cordery
Prior to Sandoz I, Arnold J had held a number of claims of Warner-Lambert’s patent for the use of pregabalin in pain invalid including claim 1 (pain) and claim 3 (neuropathic pain) (“Warner-Lambert V” according to Arnold J’s nomenclature). [read post]
27 Jun 2008, 2:55 pm
Lambert, No. 04-35998 (6-27-08). [read post]
16 Jul 2019, 1:54 am
Mr Justice Arnold was doubtful of this "since the skilled person is located in the UK" (Generics v Warner Lambert, [2015] EWHC 2548 (Pat)) (para. 118). [read post]
16 Oct 2010, 9:32 am by Thom Lambert
United States, 559 F.2d 1258 (4th Cir. 1977); Atkins v. [read post]
9 Mar 2011, 7:33 am by A. Benjamin Spencer
Lloyd's of London, 135 F.3d 1289, 1292 (9th Cir.1998) (applying Rule 12(b)(3) to an international forum-selection clause); Lambert v. [read post]
9 Mar 2011, 7:36 am by A. Benjamin Spencer
Lloyd's of London, 135 F.3d 1289, 1292 (9th Cir.1998) (applying Rule 12(b)(3) to an international forum-selection clause); Lambert v. [read post]
11 Nov 2015, 3:22 pm
 On Monday this Kat posted "When litigants must be responsible -- and what happens when they're not: Lyrica pregabalin injunction is continued" (here), this being a short note on the decision of Mr Justice Arnold in Warner-Lambert Co LLC v Sandoz GmbH, Sandoz Ltd and Lloyds Pharmcacy Ltd [2015] EWHC 3153 (Pat), in the Patents Court, England and Wales, to extend an interim injunction in an ongoing patent infringement dispute over pregabalin, a generic version of… [read post]
22 Feb 2015, 10:20 pm
Here’s an interesting new case on the scope of cell phone warrants: United States v. [read post]
3 Aug 2012, 6:41 pm by Ron Miller
In view of Lambert’s holding that a complaint made to a supervisor does not suffice, the employee did not state a claim for unlawful retaliation under the FLSA, declared the court. [read post]
29 Jul 2013, 2:24 am
 As recited in the judgment, in 2010 Teva engaged in correspondence with Warner-Lambert stating that it intended to launch generic atorvastatin in November 2011 (after the expiry of the relevant SPC) but then "surreptitiously launched the product on a very large scale in June 2011, before expiry, and without any notice to the patentee." [read post]